1. Scrip
  2. >>Therapy Areas
  3. >>Alimentary/Metabolic

1Q EARNINGS: BMS sees sales slide, plans nivolumab rolling BLA

 
• By Mandy Jackson

Bristol-Myers Squibb reported a 1% drop in first quarter revenue to $3.81bn, but investors and analysts were more focused on the company's research and development pipeline – namely, the cancer immunotherapy nivolumab – than its commercial portfolio.

Bristol-Myers Squibb reported a 1% drop in first quarter revenue to $3.81bn, but investors and analysts were more focused on the company's research and development pipeline – namely, the cancer immunotherapy nivolumab – than its commercial portfolio.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Alimentary/Metabolic

More from Therapy Areas

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.

Telix Moves TLX101 Forward On Encouraging Early Brain Cancer Data

 
• By Alaric DeArment

The company is planning to start a registrational program on its home turf in Australia and is planning to bring the therapy to the US as well.

Leqembi Launch Set For Germany And Austria As EU Approval Finally Comes

 
• By Neena Brizmohun

Eisai is working on securing reimbursement across the EU for Leqembi now that the Alzheimer’s disease treatment has secured marketing approval from the European Commission.